COPENHAGEN/LONDON (Reuters) - Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and ...

COPENHAGEN/LONDON >> Obesity drug maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes drug ...

Novo Nordisk is ramping up the manufacturing capacity of its obesity-related drugs as demand for Wegovy and Ozempic continues to surge. It's pouring $4.1 billion to expand its facility.

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.

Topline. Danish pharma giant Novo Nordisk on Friday announced plans to spend $6 billion to boost manufacturing capacity, amid booming demand for its wildly popular weight loss and diabetes drugs ...

Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes drug Ozempic, it said on ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.